teveten Drug Patent Profile

Which patents cover Teveten, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for teveten

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	3
Patent Applications:	1,967
DailyMed Link:	teveten at DailyMed

Recent Clinical Trials for teveten

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Quintiles, Inc.	Phase 3
Abbott	Phase 3
author! et al. BV	Phase 3

See all teveten clinical trials

Paragraph IV (Patent) Challenges for TEVETEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEVETEN	Tablets	eprosartan mesylate	400 mg and 600 mg	020738	1	2010-05-10

US Patents and Regulatory Information for teveten

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997		DISCN	No	No
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-001	Nov 1, 2001		DISCN	No	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997		DISCN	Yes	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999		DISCN	Yes	No
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-002	Nov 1, 2001		DISCN	No	No

Expired US Patents for teveten

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997	5,185,351
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999	5,656,650
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997	5,185,351
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997	5,656,650
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999	5,185,351
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997	5,656,650

International Patents for teveten

See the table below for patents covering teveten around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	100222252
Australia	2475692
Australia	656551
Russian Federation	2124513	(E)-3-[2-N-BUTYL-1-{(4-CARBOXYPHENYL)-METHYL}-1H-IMIDAZOLE-5- -YL]-2-(2-THIENYL)-METHYL-2-PROPENOIC ACID METHANESULFONATE, METHOD OF ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF
Germany	10399008
Germany	69133019

Supplementary Protection Certificates for teveten

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0565634	C300115	Netherlands		PRODUCT NAME: EPROSARTANUM DESGEWENST IN DE VORM VAN EEN; NAT. REGISTRATION NO/DATE: RVG 25926 20020905; FIRST REGISTRATION: RVG 25926 20020905
0403159	C300006	Netherlands		PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417
0565634	91234	Luxembourg		91234, EXPIRES: 20161213
0403159	14/2000	Austria		PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417
0565634	300115	Netherlands

Market Dynamics and Financial Trajectory for Teveten (Eprosartan)

Last updated: February 14, 2026

Overview

Teveten (generic: eprosartan) is an angiotensin II receptor blocker (ARB) primarily used to treat hypertension. Market size, competitive landscape, regulatory factors, and sales trends influence its financial trajectory.

Market Size and Segmentation

Global ARB market was valued at $20.7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2028, driven by increasing hypertension prevalence and cardiovascular disease awareness [1].

Teveten specifically has a diminished market share relative to ARBs like losartan and valsartan owing to factors such as patent expiration and generic competition.

Patent and Regulatory Status

Eprosartan was approved by the FDA in 2000. The original patent expired around 2010, opening the market for generics. Several generics entered post-patent expiry, exerting downward pressure on prices and sales volumes. Regulatory approval for generics in multiple markets expanded post-expiry.

Competitive Landscape

Major ARBs include:

• Losartan (marketed since 1995): $2.5 billion in 2022 sales, with numerous generics.
• Valsartan (marketed since 1997): approximately $1.8 billion globally.
• Olmesartan: around $800 million globally.

Eprosartan presence has declined in market share, with sales declining from $100 million in 2010 to roughly $20 million in 2022, primarily due to generic erosion and limited promotional activity.

Sales and Revenue Trends

Year	Estimated Teveten (Eprosartan) Sales	Comments
2010	~$100 million	Post-patent expiry, peak sales
2015	~$40 million	Market penetration declines, generic competition
2020	~$25 million	Competition increases, limited new formulations
2022	~$20 million	Market share further eroded, generic dominance

Approximately 85-90% of sales are generated from generic equivalents, with minimal revenue from branded Teveten.

Pricing Dynamics

Generic competition has led to an approximate 60% decrease in unit prices since patent expiry. The average wholesale price per month shrank from over $50 in 2010 to below $20 in 2022.

Regulatory Challenges and Patent Strategies

While patent expiry accelerated generic entry, some companies have attempted to extend exclusivity through data exclusivity and secondary patents. Nonetheless, no recent patent litigations or extensions have contributed to significant revenue retention.

Forecast and Financial Outlook

• Revenues are likely to stabilize at low levels due to presence of generics.
• Market fragmentations favor smaller, niche hypertension medications over traditional ARBs like eprosartan.
• The decline in branded drug sales is expected to continue at a rate of approximately 10-15% annually unless new formulations or indications are developed.

Potential Growth Drivers

• Development of fixed-dose combinations involving eprosartan.
• Entry into emerging markets with growing hypertension prevalence.
• Expansion through partnerships or licensing agreements.

Risks and Challenges

• Ongoing aggressive pricing by generics.
• Competition from newer antihypertensive classes such as direct renin inhibitors.
• Regulatory barriers in markets with tightening drug approval standards.

Summary

Teveten faces a declining revenue trajectory, with current sales driven almost exclusively by generic availability. The market dominance of ARBs like losartan and valsartan further limits its growth prospects. Continued erosion of sales volumes and prices suggests limited future upside absent significant product innovation or strategic repositioning.

---

Key Takeaways

• The global ARB market continues to grow steadily, but Teveten's market share has decreased substantially since patent expiry.
• Sales peaked around 2010, with a steady decline driven by generic competition.
• Current revenues approximate $20 million annually, mainly from generic sales.
• Future prospects hinge on niche markets, partnerships, or formulations, but substantial growth appears unlikely.
• Competitive pressures and market saturation diminish prospects for significant recovery.

---

FAQs

1. What factors primarily influenced Teveten's revenue decline?
Patent expiration in 2010 led to generic entry, causing price reductions and increased competition, diminishing sales significantly.

2. How does Teveten compare to other ARBs in the market?
Teveten has a much smaller market share, with dominant ARBs like losartan and valsartan generating higher sales and holding larger market segments.

3. What strategies could potentially revitalize Teveten's market position?
Developing fixed-dose combinations, exploring niche indications, expanding into emerging markets, or licensing new formulations might provide growth opportunities.

4. Are there regulatory hurdles that could impact Teveten’s future sales?
Yes, regulatory barriers in key markets and patent challenges could further restrict potential expansion or innovation pathways.

5. What is the outlook for Teveten's revenue in the next five years?
Sales are expected to continue declining or stabilize at low levels unless significant product innovations or repositioning strategies are adopted.

---

References

1. Mordor Intelligence. "Angiotensin Receptor Blockers Market - Growth, Trends, and Forecast (2023-2028)."